Statement 8: Statement of Risks (Continued)
Contingent assets — unquantifiable
Health and Ageing
Legal action seeking compensation from Sanofi‑Aventis
The Department of Health and Ageing has initiated legal action to seek compensation from Sanofi‑Aventis, the original patent owner of clopidogrel (Plavix®), for additional costs to the Pharmaceutical Benefits Scheme (PBS) resulting from a delay in listing a generic version of clopidogrel. Listing a generic form of clopidogrel on the Australian market in 2007 would have triggered an automatic reduction to the price paid by the Government for clopidogrel through the PBS. The first generic version of this medicine was listed in 2010.
Industry, Innovation, Science, Research and Tertiary Education
Wireless Local Area Network
The Commonwealth Scientific and Industrial Research Organisation (CSIRO) is currently involved in legal proceedings in the United States related to a wireless local area network patent which CSIRO owns and wishes to license broadly. The proceedings are additional to proceedings settled by agreement in 2009 and 2012 and are at various phases. If successful, CSIRO expects to receive additional revenue which would exceed the associated legal costs. At this stage, the revenue and costs are unquantifiable.
If www.budget.gov.au responds slowly or you are having trouble downloading a document, try one of the Budget Website Mirrors
Note: Where possible, Budget documents are available in HTML and for downloading in Portable Document Format(PDF). If you require further information on any of the tables or charts on this website, please contact The Treasury.
